research reports and media, page-4364

JT, it's so good to see at least some longer termers still here, it's been quite the disco so far, I know a few are saying we are at the wrong club haha

Yeah I agree with you, things look quiet and so much patience is required to stick with it (I was just speaking to a pal and asking him if it seems it's arduous because we look at it so often and are presumably more across it than the average shareholder in terms of science and what the product does and is capable of?)...

IF we get a relatively smooth green light whenever it arrives, there will be a lot of pathways and options on the table, my views. I think there will be a lot of current and new holders that will finally get excited that we are about to genuinely start. Most know how consistent the data and the drug is. Yes the road is still long, but it will potentially get all the more golden as we progress.


DYOR